News | Blood Testing | April 13, 2017

New Study Pursues Universal Sample Bank for Troponin Tests

Researchers hope to improve consistency among blood tests used to diagnose heart attacks

New Study Pursues Universal Sample Bank for Troponin Tests

April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC) Journal of Applied Laboratory Medicine describes the creation of a first-of-its-kind patient sample bank that could improve consistency among blood tests used to diagnose heart attacks and advance care for cardiac patients.

In the emergency room, a blood test for cardiac troponin — a protein released when cardiac cells are damaged — is used to identify chest pain patients who are having a heart attack so that they can be treated as quickly as possible. Specifically, a heart attack is diagnosed when a patient’s troponin concentrations exceed those found in the 99th percentile of a healthy reference population. However, the 99th percentile cutoff value varies for different troponin tests because each test manufacturer uses a different reference population. Therefore, there is a need to have samples available from one healthy reference population so that all manufacturers can use the same population to determine a universal 99th percentile cutoff for troponin. This will help to ensure that cardiac patients receive the same diagnosis and quality of care regardless of what hospital they go to and what troponin test is used.

This study examines the universal sample bank of ethnically and geographically diverse healthy subjects that AACC created to ensure that cardiac patients have consistent quality of diagnosis and care. Participants were recruited from among attendees of the 2015 AACC Annual Meeting & Clinical Lab Expo, the world’s largest conference for laboratory medicine, as well as at the University of Maryland. From those individuals who met initial eligibility criteria, 60 mL of blood was collected and tested for hemoglobin A1c, N-terminal pro–B-type natriuretic peptide and creatinine. These tests were used to exclude participants with uncontrolled diabetes, renal insufficiency, and heart disease, including most asymptomatic cardiac conditions.

In total, 808 individuals were included in the sample bank: 402 females and 406 males who are 60 percent Caucasian, 26 percent African or African American, 11 percent Asian or Pacific Islander, and 3 percent other. This sample bank and its associated data provides a unique opportunity for diagnostic manufacturers to generate a reliable 99th percentile value that applies to all troponin tests, which in turn could prevent delays in heart attack patients receiving critical treatment.

“The 99th percentiles can now be assessed by assay manufacturers and laboratories using the same patient population,” said senior paper author Robert Christenson, Ph.D., of the University of Maryland School of Medicine. “This enables establishing and applying clinical decision points in an effective and consistent manner. [Additionally,] this sample bank can and likely will be used for the determination of reference ranges for other clinical laboratory tests.”

For more information: www.aacc.org

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing | March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Frost & Sullivan, biomarkers, cardiac disease diagnosis, analysis
News | Blood Testing | January 12, 2016
Even though brain natriuretic peptide (BNP)/pro-BNP and troponin biomarkers are the gold standard for cardiac disease...
Overlay Init